Profile data is unavailable for this security.
About the company
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
- Revenue in USD (TTM)39.57m
- Net income in USD-165.37m
- Incorporated2017
- Employees284.00
- LocationBicycle Therapeutics PLCBlocks A & B, Portway Building, Granta PCAMBRIDGE CB21 6GSUnited KingdomGBR
- Phone+44 122 326 1503
- Websitehttps://www.bicycletherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics Inc | 0.00 | -185.98m | 1.54bn | 50.00 | -- | 7.06 | -- | -- | -15.42 | -15.42 | 0.00 | 7.37 | 0.00 | -- | -- | 0.00 | -54.73 | -101.87 | -87.47 | -118.83 | -- | -- | -- | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| CareDx Inc | 297.08m | -159.64m | 1.58bn | 635.00 | -- | 5.94 | -- | 5.30 | -2.99 | -2.99 | 5.62 | 5.03 | 0.6053 | 5.46 | 5.04 | 467,848.80 | -32.53 | -17.54 | -38.52 | -20.85 | 64.98 | 65.50 | -53.73 | -27.78 | 3.85 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Syndax Pharmaceuticals Inc | 3.50m | -264.08m | 1.59bn | 112.00 | -- | 3.65 | -- | 452.96 | -3.38 | -3.38 | 0.0447 | 5.11 | 0.0077 | -- | 0.6132 | 31,250.00 | -58.15 | -27.90 | -63.20 | -30.15 | -- | -- | -7,545.20 | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
| Nurix Therapeutics Inc | 62.30m | -165.00m | 1.61bn | 284.00 | -- | 4.35 | -- | 25.91 | -2.92 | -2.92 | 1.10 | 5.76 | 0.1446 | -- | -- | 219,376.80 | -38.30 | -33.01 | -46.57 | -39.66 | -- | -- | -264.84 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Kura Oncology Inc | 0.00 | -181.75m | 1.62bn | 142.00 | -- | 3.46 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 382.24m | -145.93m | 1.69bn | 536.00 | -- | -- | -- | 4.41 | -0.7301 | -0.7301 | 1.90 | -2.30 | 0.7627 | 0.3747 | 6.05 | 713,126.90 | -29.12 | -47.95 | -37.43 | -64.89 | 98.46 | 97.06 | -38.18 | -114.94 | 2.78 | -0.6999 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Viridian Therapeutics Inc | 288.00k | -228.06m | 1.72bn | 96.00 | -- | 4.36 | -- | 5,964.55 | -4.25 | -4.25 | 0.0053 | 8.29 | 0.0006 | -- | 5.65 | 3,063.83 | -48.67 | -55.59 | -52.32 | -60.32 | -- | -- | -79,185.77 | -5,678.12 | -- | -- | 0.0372 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Arvinas Inc | 93.30m | -323.40m | 1.76bn | 445.00 | -- | 2.93 | -- | 18.84 | -5.29 | -5.29 | 1.47 | 8.75 | 0.079 | -- | 12.61 | 209,662.90 | -27.36 | -22.01 | -37.83 | -26.47 | -- | -- | -346.52 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Bicycle Therapeutics PLC (ADR) | 39.57m | -165.37m | 1.76bn | 284.00 | -- | 2.01 | -- | 44.46 | -3.81 | -3.81 | 0.8962 | 12.67 | 0.0524 | -- | 1.75 | 139,345.10 | -21.88 | -29.45 | -24.15 | -32.98 | -- | -- | -417.88 | -571.36 | -- | -- | 0.0342 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
| MannKind Corp | 248.37m | 11.74m | 1.84bn | 414.00 | 186.79 | -- | 106.40 | 7.42 | 0.0359 | 0.0359 | 0.834 | -0.8226 | 0.656 | 2.85 | 9.71 | 599,937.20 | 3.10 | -26.07 | 4.05 | -37.80 | 71.29 | 59.68 | 4.73 | -57.61 | 3.76 | 1.86 | 1.89 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Kiniksa Pharmaceuticals Ltd | 338.93m | -10.23m | 1.87bn | 297.00 | -- | 4.29 | -- | 5.52 | -0.1788 | -0.1788 | 4.68 | 6.12 | 0.6602 | 1.41 | 15.03 | 1,141,179.00 | -1.99 | -16.49 | -2.29 | -18.72 | 87.73 | -- | -3.02 | -53.64 | 3.16 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Mirum Pharmaceuticals Inc | 264.38m | -109.16m | 1.88bn | 294.00 | -- | 8.17 | -- | 7.10 | -2.40 | -2.40 | 5.81 | 4.81 | 0.4788 | 5.06 | 5.52 | 1,001,424.00 | -19.77 | -38.93 | -23.38 | -44.88 | 72.27 | -- | -41.29 | -190.71 | 3.09 | -- | 0.573 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -253.26m | 1.94bn | 268.00 | -- | 5.05 | -- | -- | -2.79 | -2.79 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -55.77 | -35.26 | -60.57 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0522 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Akero Therapeutics Inc | 0.00 | -204.18m | 1.94bn | 61.00 | -- | 2.43 | -- | -- | -3.41 | -3.41 | 0.00 | 11.53 | 0.00 | -- | -- | 0.00 | -26.71 | -37.73 | -27.66 | -40.13 | -- | -- | -- | -- | -- | -- | 0.042 | -- | -- | -- | -35.46 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 49.64m | -374.93m | 1.96bn | 500.00 | -- | 3.34 | -- | 39.46 | -1.63 | -1.63 | 0.2155 | 2.08 | 0.0688 | -- | 17.80 | 99,270.00 | -51.98 | -- | -60.35 | -- | 17.15 | -- | -755.37 | -- | -- | -- | 0.0504 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Bicycle Therapeutics PLC's reporting currency: US Dollar USD
52.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2024 | 9.40m | 19.79% |
| Deep Track Capital LPas of 30 Jun 2024 | 3.49m | 7.35% |
| RA Capital Management LPas of 30 Jun 2024 | 2.25m | 4.74% |
| Armistice Capital LLCas of 30 Jun 2024 | 1.97m | 4.15% |
| Westfield Capital Management Co. LPas of 30 Jun 2024 | 1.52m | 3.21% |
| Tybourne Capital Management (HK) Ltd.as of 30 Jun 2024 | 1.51m | 3.18% |
| First Light Asset Management LLCas of 30 Jun 2024 | 1.38m | 2.92% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.21m | 2.54% |
| Fairmount Funds Management LLCas of 30 Jun 2024 | 1.07m | 2.25% |
| Polar Capital LLPas of 30 Jun 2024 | 1.00m | 2.12% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
